Oxford Biodynamics Strong position playing a role in the fight against the coronavirus

Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch™, expects to announce its interim results for the half-year ended 31 March 2020 on 16 June 2020.

The Group also provided an update on the actions it is taking in response to the COVID-19 pandemic. The Group remains in a strong position and is pleased to be playing a role in the fight against the coronavirus.

Trading update and response to COVID-19

OBD was pleased to announce on 30 April its involvement in the Chief Scientist Office of Scotland-funded GETAFIX clinical study alongside Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland. The Group’s Episwitch™ technology was chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the study. Our contribution to this important study will be a priority, along with ongoing work on existing projects, over the coming few months.

The Group’s newly-appointed Chief Executive Officer, Dr Jon Burrows, joined the Company in late March. Jon has been working closely with OBD’s senior executives to position the Group to be ready to benefit from the adoption of its unique and valuable technology platform, EpiSwitch™, by a growing customer base.

The COVID-19 pandemic has already had an impact, which is expected to continue, on the timing of certain existing projects, directly as a result of delays in receipt of blood samples, especially from cohorts of patients who are considered particularly vulnerable to serious illness from a COVID-19 infection. In addition, travel restrictions worldwide have impacted business development activity. The likely severity and duration of the pandemic and its impact on OBD’s customers’ activities remains uncertain. In light of the open-ended nature of the crisis and associated impact on the Company’s operations, the Board is unable to provide guidance for the current fiscal year. The Company will provide further updates to the market as and when there is greater clarity on the impact of COVID-19 on its operations and business development activities.

Notwithstanding these issues, the Group is in a strong position to navigate the current crisis. Cash and fixed term deposits at 30 September 2019 were £15.5m, sufficient to fund planned activity for several years. To date, none of the Company’s UK employees has been put on furlough. The Group does not expect to need to apply for support under the Coronavirus Business Interruption Loan Scheme. Activity continues on several projects including the receipt, in April 2020, of the first patient samples to be analysed under the master services agreement announced on 20 December 2019, which granted a major US pharmaceutical company access to OBD’s unique EpiSwitch™ technology for use in the development of predictive biomarkers.

The Company is doing everything possible to keep its employees safe. To this end, since the announcement of ‘lockdown’ guidance and a movement control order by the UK and Malaysian governments respectively, most OBD staff have been working remotely from home. Small teams of essential laboratory personnel have continued to work at our facilities, following strict social distancing rules.

Jon Burrows, CEO, comments “It is without doubt both an exceptional and exciting time to have joined OBD as its CEO. Whilst this is of course a difficult time for many throughout the world, it is inspiring to be leading OBD as we play our part in the global research-driven fight against coronavirus. Additionally, I am pleased that we have been able to continue to support our customers and staff during these uncertain times. After several weeks in my post now, I am extremely positive about the position of the Company and I look forward to providing a more detailed update in June.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    How are EpiSwitch markers detected?

    Introduction: Getting the basics right Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA is often

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role in the proteasome,

    Oxford BioDynamics

    New questions about Covid-19

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more at risk,

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and access to

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities such as

    Oxford BioDynamics

    ALS Awareness

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in response to

    Oxford BioDynamics

    ALS Awareness Month This May

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated the letters

    Oxford BioDynamics

    Microarray Facility

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of multiplex formats

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that integrate environmental

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques) outside neurons

    No more posts to show